A BP that believes Vascepa lowers CV event risk and is willing to put the time and $ into running a new small independent ( hopefully short ) trial in the EU ( where we have patent protection ) ...to independently confirm R-IT results in a high risk EU population, in partnership with those health authorities.
Look what Novartis has done with Inclisiran ...after they got that from Denner ( MDCO ) ...see my earlier posts . Novartis is the obvious candidate ....how low would the PPS have to go to entice them ?.....assuming they believe in Vascepa RR Novartis already has the EU marketing structure in place for CV risk reduction .....and Vascepa is the obvious Add on to Leqvio
Market Data 
Markets 
AI
